Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT05386550
Title Phase III Xevinapant (Debio 1143) and Radiotherapy in Resected LA SCCHN, High Risk, Cisplatin-ineligible Participants (XRAY VISION)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors EMD Serono Research & Development Institute, Inc.
Indications

hypopharynx cancer

oral squamous cell carcinoma

oropharynx cancer

laryngeal squamous cell carcinoma

Therapies

Xevinapant

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.